Key result
DOACs match warfarin for ischemic stroke prevention in HF but carry lower bleeding risk.
Why the study?
The study was conducted to compare the effectiveness and safety of anticoagulants in patients with atrial fibrillation and concomitant conditions, including heart failure.
Do different anticoagulants (warfarin, dabigatran, edoxaban, rivaroxaban) and aspirin differ in their efficacy and safety for preventing stroke and systemic embolism in patients with atrial fibrillation and heart failure?
Do different anticoagulants (warfarin, dabigatran, edoxaban, rivaroxaban) and aspirin differ in their efficacy and safety for preventing stroke and systemic embolism in patients with atrial fibrillation and heart failure?
Direct oral anticoagulants offer a safer alternative to warfarin with comparable efficacy for stroke prevention in patients with heart failure and atrial fibrillation, primarily driven by a reduction in intracranial bleeding.
Supports considering DOACs over warfarin in heart failure and atrial fibrillation; leaves open need for dedicated randomized trials.
This article summarizes the findings of research aimed at comparing the effectiveness of anticoagulants in patients with atrial fibrillation and concomitant conditions, including heart failure. The studies evaluated the impact of warfarin, aspirin, dabigatran, edoxaban, and rivaroxaban on the risk of stroke, systemic embolisms, and bleeding events. The results indicate significant differences in the efficacy and safety of these medications: warfarin reduces the risk of stroke but increases the likelihood of bleeding; edoxaban and rivaroxaban showed a decrease in bleeding risk while maintaining efficacy in stroke prevention. The research also identified the stability of drug effects based on the severity of heart failure, emphasizing the need for an individualized approach to treatment selection in this patient group.
No takes yet. Share an insight, caveat, or question.
Sultan et al. (2024) conducted a review in Heart failure and atrial fibrillation. Warfarin and direct oral anticoagulants (dabigatran, edoxaban, rivaroxaban) vs. Aspirin or each other was evaluated. Warfarin reduces the risk of ischemic stroke in heart failure patients but increases bleeding risk, whereas direct oral anticoagulants provide comparable stroke prevention with lower bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: